azacitidine has been researched along with everolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borghi, MO; Cantone, MC; Caraglia, M; Di Blasio, AM; Dicitore, A; Gaudenzi, G; Gelmini, G; Gentilini, D; Grassi, ES; Hofland, LJ; Misso, G; Pepe, D; Persani, L; Vitale, G | 1 |
1 review(s) available for azacitidine and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for azacitidine and everolimus
| Article | Year |
|---|---|
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.
Topics: Azacitidine; Carcinoma, Neuroendocrine; Decitabine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Neoplasm Proteins; Thyroid Neoplasms | 2017 |